New anti-VEGF agents for wet age-related macular degeneration can extend injection intervals to 3-5 months but may increase ...

LONG BEACH, Calif. -- Outcomes in neovascular age-related macular degeneration (nAMD) failed to improve with the addition of ...

Iluvien for diabetic macular edema demonstrated longer-lasting intervals between injections and noninferior visual acuity ...

Pavblu, an Eylea HD biosimilar, shows stable vision outcomes and minimal side effects in real-world use, promising a reliable ...

Investigators defined an IOP spike as >40 mm Hg or an increase ≥10 mm Hg after injection. The population was older (mean age ...

D Molecular's 4D-150 showed sustained vision and anatomical improvements with fewer injections in DME, supported by ...

In 2023, the FDA approved aflibercept 8 mg for wet AMD, DME, and diabetic retinopathy. The manufacturer touted the dose as beneficial for patients since they could go 8 weeks or more between doses ...

Aflibercept, marketed as Eylea®, is designed to treat various retinal conditions by inhibiting vascular endothelial growth factor (VEGF), thus reducing abnormal blood vessel growth and leakage.

Intravitreal injections of aflibercept every 4 weeks after monthly injections may provide an additional benefit to patients with early persistent fluid from neovascular age-related macular ...

Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the aflibercept arm Study Enrolled Treatment-Naïve, or Almost Naïve, Patients ...

TORONTO, Ontario — Switching patients to intravitreal aflibercept predictably results in anatomic, but not visual, improvements in patients with wet age-related macular degeneration who have ...